{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:25:05Z","timestamp":1793143505651,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.vhri.2023.03.006","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:46:00Z","timestamp":1684431960000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China"],"prefix":"10.1016","volume":"37","author":[{"given":"Ziyi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10100","key":"10.1016\/j.vhri.2023.03.006_bib1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"GBD 2016 Causes of Death Collaborators, Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vhri.2023.03.006_bib2","first-page":"111","article-title":"Distribution of lymphoma subtypes in China: analysis of 10002 domestic multi-center cases","volume":"11","author":"Li","year":"2012","journal-title":"Theor Pract Diagn"},{"issue":"16","key":"10.1016\/j.vhri.2023.03.006_bib3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.vhri.2023.03.006_bib4","series-title":"Relapsed\/refractory diffuse large B-cell lymphoma","first-page":"498","volume":"2011","author":"Friedberg","year":"2011"},{"issue":"11","key":"10.1016\/j.vhri.2023.03.006_bib5","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemoimmunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.vhri.2023.03.006_bib6","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","article-title":"Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment","volume":"94","author":"Hitz","year":"2015","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2023.03.006_bib7","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1182\/blood-2018-99-114434","article-title":"JWCAR029 is a CD19-targeted CAR-T cell product with process and quality controls delivered as a flat dose of CAR-T cell to patients with NHL","volume":"132","author":"Wang","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vhri.2023.03.006_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","article-title":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med"},{"issue":"suppl 16","key":"10.1016\/j.vhri.2023.03.006_bib9","article-title":"Two-year follow-up result of RELIANCE study, a multicenter phase 2 trial of relmacabtagene autoleucel in Chinese patients with relapsed\/refractory large B-cell lymphoma","volume":"40","author":"Ying","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2023.03.006_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.vhri.2023.03.006_bib11","author":"Sang"},{"issue":"2","key":"10.1016\/j.vhri.2023.03.006_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s41669-021-00260-z","article-title":"Mixture cure models in oncology: a tutorial and practical guidance","volume":"5","author":"Felizzi","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"10.1016\/j.vhri.2023.03.006_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"27","key":"10.1016\/j.vhri.2023.03.006_bib16","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.vhri.2023.03.006_bib17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2023.03.006_bib18","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jval.2018.09.433","article-title":"PCN351 \u2013 health-state utility values in diffuse large B-cell lymphoma","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.vhri.2023.03.006_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/bmt.2010.304","article-title":"A\u00a0prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up","volume":"46","author":"Fr\u00f6din","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.vhri.2023.03.006_bib21","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2217\/fon-2020-0946","article-title":"Health-related quality of life and utility outcomes with selinexor in relapsed\/refractory diffuse large B-cell lymphoma","volume":"17","author":"Shah","year":"2021","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2023.03.006_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026309","article-title":"End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study","volume":"9","author":"Li","year":"2019","journal-title":"BMJ Open"},{"issue":"06","key":"10.1016\/j.vhri.2023.03.006_bib30","first-page":"18","article-title":"Status of stem cell mobilization and collection and disease burden of autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma","volume":"14","author":"Yi","year":"2019","journal-title":"Chinese Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vhri.2023.03.006_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.vhri.2023.03.006_bib23","first-page":"6113","article-title":"Cost-effectiveness analysis of axicabtagene ciloleucel\u00a0vs. salvage chemotherapy for relapsed or refractory adult diffuse\u00a0large B-cell lymphoma in China","volume":"30","author":"Li","year":"2022","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.vhri.2023.03.006_bib24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jval.2016.04.011","article-title":"Accounting for cured patients in cost-effectiveness analysis","volume":"20","author":"Othus","year":"2017","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"12","key":"10.1016\/j.vhri.2023.03.006_bib26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"Med Econ"},{"issue":"11","key":"10.1016\/j.vhri.2023.03.006_bib28","first-page":"1321","article-title":"Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed\/refractory diffuse large B-cell lymphoma from Singapore\u2019s healthcare system perspective","volume":"23","author":"Cher","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.vhri.2023.03.006_bib29","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s12325-021-01767-x","article-title":"Cost-effectiveness of tisagenlecleucel in paediatric acute lymphoblastic leukaemia (pALL) and adult diffuse large B-cell lymphoma (DLBCL) in Switzerland","volume":"38","author":"Moradi-Lakeh","year":"2021","journal-title":"Adv Ther"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109923000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:45Z","timestamp":1761941685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109923000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":26,"alternative-id":["S2212109923000389"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2023.03.006","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2023.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}